{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreifkszux2yrbd253cedr7g6bsrgqxrwbziirzhpigw4wu2fjx5xcty",
    "uri": "at://did:plc:o7x3aaueo7gbdj5s6ywwl7sl/app.bsky.feed.post/3moyuvkgzsgq2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreicruhan2g2xwn2u6kizdqfrthibxpm4jwr4ilxdligszkulaipjmi"
    },
    "mimeType": "image/png",
    "size": 257545
  },
  "path": "/eli-lilly-retatrutide-access/?utm_source=rss&utm_medium=rss&utm_campaign=eli-lilly-retatrutide-access",
  "publishedAt": "2026-06-24T02:08:19.000Z",
  "site": "https://thedeepdive.ca",
  "tags": [
    "Healthcare",
    "Latest",
    "Donald Trump",
    "Eli Lilly",
    "obesity",
    "retatrutide",
    "Is Trump The Mystery Patient Who Got Lilly’s Obesity Drug Early?",
    "the deep dive"
  ],
  "textContent": "Pharmaceutical firm Eli Lilly and the Food and Drug Administration allowed a single 79-year-old man to receive retatrutide, Lilly’s still-unapproved obesity drug, through the FDA’s expanded access pathway. The request was made in April, according to STAT, which attributed the information to three people familiar with the matter who were not named because they feared […]\n\nThe post Is Trump The Mystery Patient Who Got Lilly’s Obesity Drug Early? appeared first on the deep dive.",
  "title": "Is Trump The Mystery Patient Who Got Lilly’s Obesity Drug Early?"
}